XNCR

News Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial

3d ago

News Xencor (XNCR) Q2 Revenue Jumps 82%

14d ago

News Peeling Back The Layers: Exploring Xencor Through Analyst Insights

14d ago

SEC filing XNCR Reports $611M Cash, $19.2M Revenue, +12% YoY, Announces $20M Buyback

28d ago

SEC filing XNCR Adopts Executive Severance Policy, Offers 15-Month Pay + COBRA, Bonus + Equity Acceleration in Change of Control

35d ago

Insider trade Sale by Bart Jan Cornelissen (SR. VICE PRESIDENT & CFO)

49d ago

Insider trade Sale by Celia Eckert (SVP, GENERAL COUNSEL)

84d ago

Insider trade Sale by John R Desjarlais (SR. VICE PRESIDENT & CSO)

84d ago

Insider trade Sale by Bart Jan Cornelissen (SR. VICE PRESIDENT & CFO)

84d ago

Insider trade Sale by Bassil I Dahiyat (PRESIDENT & CEO)

84d ago

News Xencor falls as royalty dispute with Astra leads to guidance cut

89d ago

Insider trade Sale by Bassil I Dahiyat (PRESIDENT & CEO)

89d ago

Insider trade Sale by Celia Eckert (SVP, GENERAL COUNSEL)

89d ago

Insider trade Sale by John R Desjarlais (SR. VICE PRESIDENT & CSO)

89d ago

News RMR Group GAAP EPS of $0.71 beats by $0.47, revenue of $180.42M misses by $10.13M

117d ago

News /C O R R E C T I O N -- Ulticam and Xthings Inc./

133d ago

News Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

136d ago

News Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy

148d ago

Scanner Unusual volume (z=4.9)

160d ago

Scanner Unusual volume (z=5.0)

162d ago

Scanner Unusual volume (z=5.0)

163d ago

Scanner Unusual volume (z=5.0)

164d ago